RxDoctor Payments DataLook up a doctor →

Harvey Serota, MD

Interventional Cardiology · Saint Louis, MONPI 1346264017

Payments from drug & device makers

$7,102,560in general payments, 2019–2025

Across 3,973 payments — averaging $1787.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$1.6M
  • Novo Nordisk AS$1.2M
  • Boehringer Ingelheim International GmbH$1.1M
  • Astrazeneca UK Limited$938K
  • Bayer$618K
  • Eli Lilly$426K
  • plus $1.2M from 52 others
$73,253in research payments, 2019–2025

Across 15 payments — averaging $4883.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Applied Therapeutics, Inc.$63K
  • Novartis$9K
  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim Pharma GmbH & Co.kg130$1,586,286
Novo Nordisk AS908$1,191,592
Boehringer Ingelheim International GmbH1,273$1,114,423
Astrazeneca UK Limited5$937,775
Bayer211$618,326
Eli Lilly5$426,089
Cvrx, Inc.27$214,267
AstraZeneca83$194,396
Merck198$164,957
Vertex8$141,752
Boehringer Ingelheim116$122,745
Johnson & Johnson108$90,667
Lilly USA, LLC58$50,687
Lexicon Pharmaceuticals, Inc.48$48,745
E.r. Squibb & Sons, L.L.C.16$48,440
Biotronik Inc.222$42,960
Esperion Therapeutics, Inc.92$34,921
Amarin Pharma, Inc.56$26,357
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)32$16,720
Vifor (international) Ltd.5$10,000
Alnylam Pharmaceuticals Inc.3$8,616
Novo Nordisk25$3,164
Novartis148$2,251
Abiomed10$1,495
Vifor Pharma, Inc.45$849
Amgen37$793
Impulse Dynamics (USA) Inc.7$730
Sanofi-aventis U.S. LLC26$392
Angiodynamics, Inc.3$288
Boston Scientific4$186
Kiniksa Pharmaceuticals International, PLC7$157
Medtronic1$152
Pfizer8$131
Livanova USA, Inc.2$125
Penumbra, Inc.1$120
Biosense Webster, Inc.1$110
Kestra Medical Technology Services, Inc.6$97
Cardiac Dimensions, Inc.1$90
Atricure, Inc.1$80
Actelion Pharmaceuticals US, Inc.4$76
United Therapeutics Corporation4$69
Daiichi Sankyo Inc.3$61
AbbVie3$52
Gilead3$45
Kiniksa Pharmaceuticals, Ltd.2$43
Resmed Corp1$34
Scpharmaceuticals Inc.2$32
Regeneron Healthcare Solutions, Inc.2$30
Arbor Pharmaceuticals, Inc.2$28
Itamar Medical Inc1$25
Corcept Therapeutics1$24
Pharmacosmos Therapeutics Inc.1$20
Cardiva Medical, Inc.1$19
Bard Peripheral Vascular, Inc.1$18
Edwards Lifesciences1$17
Amryt Pharma Holdings Ltd1$13
Janssen Research & Development, LLC2$12
Bardy Diagnostics, Inc.1$8

How this compares

$7,102,560 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri →

Medicare billing

Part B allowed, 2024
$342,186
Medicare patients
376
Services billed
7,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →